NewsBenzingaFDA Approves Roche’s Enspryng For Adults With Thyroid Eye Disease, First At-Home Subcutaneous Option; SatraGO-2 Proptosis Response 52.9% Vs 23.4% Placebo, SatraGO-1 Missed Primary Endpoint FDA Approves Roche’s Enspryng For Adults With Thyroid Eye Disease, First At-Home Subcutaneous Option; SatraGO-2 Proptosis Response 52.9% Vs 23.4% Placebo, SatraGO-1 Missed Primary Endpoint Benzinga 2026.10.16 05:47 (GMT+0) Open on Benzinga Other news ‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead Trump Administration Sued by Ecuadorian Fishermen Over Pacific Drone Strike: ‘We’re Alive by the Grace of God’ Micron Technology (MU) Stock Is Trending After Hours: Here's Why Kevin O’Leary Says Nvidia Needs Leader Who Can Manage ‘International Pressure’ as Crypto Punters Raise Odds of NVDA Stock Hitting $180 By Month-End Anthony Scaramucci Blasts Trump on FAA Meltdown: ‘Why Don’t We Start Focusing on Ourselves Now?’
‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors
Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead
Trump Administration Sued by Ecuadorian Fishermen Over Pacific Drone Strike: ‘We’re Alive by the Grace of God’
Kevin O’Leary Says Nvidia Needs Leader Who Can Manage ‘International Pressure’ as Crypto Punters Raise Odds of NVDA Stock Hitting $180 By Month-End